MTOR and colorectal cancer: Research has investigated using both autophagy activators and inhibitors together; for instance, CQ and HCQ have been shown to boost the impact of mTOR inhibitors like temsirolimus (145) or everolimus (146), in colorectal cancer (147), melanoma (145), and neuroendocrine neoplasms (146).